title: The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse.
abstract: We used a neonatal mouse model to examine the histogenesis of uterine adenomyosis, and to test whether adenomyosis is due to an abnormality in myometrial differentiation, or in extracellular matrix proteins expression. We also studied the effects of tamoxifen and estradiol on uterine development, myometrial differentiation, and organization. Female CD1 pups were treated with oral tamoxifen (1 mg/kg) (n=27) or estradiol (0.1 mg/kg) (n=24) from age 1 to 5 days. Uteri from control (n=27) and treated mice were obtained on days 2, 5, 10, 15, and 42 of age. We examined the sections histologically, using image analysis and immunohistochemistry for alpha-smooth muscle actin (alpha-SMA), desmin, vimentin, laminin, fibronectin, and estrogen receptor-alpha. Following tamoxifen exposure, all uteri showed adenomyosis by 6 weeks of age (seen as early as day 10). The inner myometrium showed thinning, lack of continuity, disorganization, and bundling. alpha-SMA expression was normal. Desmin expression normally showed a wave of maturation that was absent in tamoxifen-treated mice. In the estradiol group, adenomyosis was not observed. All uterine layers were normally developed, but hypertrophied. The inner myometrium retained its circular arrangement. There was no difference in the localization of laminin or fibronectin between groups (laminin expression was reduced in the tamoxifen treated uteri). Vimentin could not be detected in all groups. Our results suggest that the development of the inner myometrium is particularly sensitive to estrogen antagonism, and can be affected by steroid receptors modulation. Disruption of the inner myometrium may play a role in the development of uterine adenomyosis.
authors.affiliation: Reproductive Sciences Section, Department of Cancer Studies and Molecular Medicine, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester, UK. mkm7@le.ac.uk
authors.forename: Mohamed K
authors.initials: MK
authors.lastname: Mehasseb
authors.forename: S C
authors.initials: SC
authors.lastname: Bell
authors.forename: M A
authors.initials: MA
authors.lastname: Habiba
mesh_terms: D000199:Actins / Q000032:analysis; D000818:Animals; D015415:Biomarkers / Q000032:analysis; D002454:Cell Differentiation / Q000187:drug effects; D003893:Desmin / Q000032:analysis; D004715:Endometriosis / Q000196:embryology*; D004958:Estradiol / Q000494:pharmacology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D047628:Estrogen Receptor alpha / Q000032:analysis / Q000235:genetics; D005260:Female; D005353:Fibronectins / Q000032:analysis; D005865:Gestational Age; D007150:Immunohistochemistry; D007797:Laminin / Q000032:analysis; D051379:Mice; D008815:Mice, Inbred Strains; D023421:Models, Animal; D009215:Myometrium / Q000166:cytology* / Q000187:drug effects / Q000196:embryology; D013045:Species Specificity; D013629:Tamoxifen / Q000494:pharmacology*; D014746:Vimentin / Q000032:analysis
chemical_list: D000199:Actins; D015415:Biomarkers; D003893:Desmin; D004965:Estrogen Antagonists; D047628:Estrogen Receptor alpha; D005353:Fibronectins; D007797:Laminin; D014746:Vimentin; D013629:Tamoxifen; D004958:Estradiol